Skip to main content
Article thumbnail
Location of Repository

Mantle cell lymphoma-like lymphomas in c-myc-3'RR/p53+/− mice and c-myc-3'RR/Cdk4R24C mice: differential oncogenic mechanisms but similar cellular origin

By Pauline Rouaud, Rémi Fiancette, Christelle Vincent-Fabert, Virginie Magnone, Michel Cogné, Pierre Dubus and Yves Denizot

Abstract

Mantle cell lymphoma (MCL) is a malignant lymphoproliferative B-cell disorder that does not occur spontaneously in mice but experimental mice model have been developed. Recently two different mice models prone to develop MCL-like lymphomas were generated: c-myc-3'RR/Cdk4R24C mice and c-myc-3'RR/p53+/− mice. Comparison of their gene expression profiles does not highlight specific differences other than those in relation with their specific mutational status (i.e., Cdk4R24C mutation or p53 mutation). We propose that similarly to typical human MCL and its blastoid or cyclin-D1 variants that correspond to the same genetic entity, MCL-like lymphomas of c-myc-3'RR/p53+/− mice and c-myc-3'RR/Cdk4R24C mice represent a spectrum of the same entity

Topics: Methodological Reports
Publisher: Impact Journals LLC
OAI identifier: oai:pubmedcentral.nih.gov:3388189
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. Al-Saleem T: Murine model for mantle cell lymphoma.
    2. Ambrus JL Jr: Development of a murine model for blastoid variant mantle-cell lymphoma.
    3. Campo E: Advances in the understanding of mantle cell lymphoma.
    4. Denizot Y: A defect of the INK4-Cdk4 checkpoint and c-myc collaborate in blastoid mantle cell lymphoma (MCL)-like lymphoma formation in mice.
    5. Denizot Y: A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3’ regulatory region-driven c-myc transgene.
    6. Denizot Y: The IgH 3’ regulatory region and its implication in lymphomagenesis.
    7. Insulators to improve expression of a 3’IgH LCRdriven reporter gene in transgenic mouse models.
    8. (2008). K: CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene
    9. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia.
    10. Lozano G: p53-dependent senescence delays Eµ-mycinduced B-cell lymphomagenesis. Oncogene 2010;29:1260-
    11. Novel targeted therapies for mantle cell lymphoma.
    12. Obesity and the risk for haematological malignancy: leukaemia, lymphoma, or myeloma. The oncologist 2010;15:1083-1101.
    13. OJ: Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53.
    14. The 3’ IgH locus control region is sufficient to deregulate a c-myc transgene and promote mature B cell malignancies with a predominant Burkitt-like phenotype.
    15. The cytoskeleton and cancer.
    16. The IgH locus 3’ regulatory region: pulling the strings from behind.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.